Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct;30(4):705-708.
doi: 10.3350/cmh.2024.0372. Epub 2024 May 20.

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis"

Toru Nakamura  1 , Masahito Nakano  1 , Tsubasa Tsutsumi  1 , Keisuke Amano  1 , Takumi Kawaguchi  1
Affiliations
Editorial

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis"

Toru Nakamura et al. Clin Mol Hepatol. 2024 Oct.
No abstract available

Keywords: Alcohol-related liver disease; Hepatitis B virus; Hepatitis C virus; Hepatoma; Metabolic dysfunction-associated fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Takumi Kawaguchi received lecture fees from ASKA Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., AbbVie GK., Eisai Co., Ltd., Novo Nordisk Pharma Ltd., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd., EA Pharma Co., Ltd. The other author has no conflicts of interest.

Comment on

References

    1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–209. - PubMed
    1. Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28:150–163. - PMC - PubMed
    1. Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2022;52:422–432. - PubMed
    1. Fukunaga S, Nakano D, Tsutsumi T, Kawaguchi T, Eslam M, Yoshinaga S, et al. Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatol Res. 2022;52:699–711. - PubMed
    1. Fukunaga S, Mukasa M, Nakane T, Nakano D, Tsutsumi T, Chou T, et al. Impact of non-obese metabolic dysfunctionassociated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study. Hepatol Res. 2024;54:201–212. - PubMed

LinkOut - more resources